Track topics on Twitter Track topics that are important to you
Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have recently licensed our lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. We have retained the rights for epratuzumab in oncology indications for which UCB has been granted a buy-in option. UCB has development, manufacture and commercialization rights, and is responsible for all clinical trials evaluating epratuzumab for the treatment of patients with moderate and severe lupus. At present, there is no cure for lupus and no new lupus drug has been approved in the U.S. in the last 40 years. We believe that our portfolio of intellectual property, which includes approximately 108 patents issued in the United States, and more than 250 other issued patents worldwide, protects our product candidates and technologies. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel dock and lock methodology, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We have transitioned our focus away from the development of diagnostic imaging products in order to accelerate the development of our therapeutic product candidates. Consistent with our de-emphasis on our diagnostic business, we no longer commercialize CEA-Scan®. LeukoScan® will continue to be manufactured and commercialized by us in territories where regulatory approvals have been granted. Furthermore, as of June 30, 2006, research and development into diagnostic product candidates was no longer a material portion of our business.
300 American Road
United States of America
Phone: 973 605 8200
Fax: 973 605 8282
Michael Pehl has been appointed president and CEO of cancer drug developer Immunomedics (NASDAQ: IMMU). Pehl comes to the Morris Plains, NJ, company from Celgene (NASDAQ: CELG), where he was president...
IMMU Stock: The Path of Least Resistance Is Geared Towards Higher Stock Prices On August 23, 2017, I focused on Immunomedics, Inc. (NASDAQ: IMMU) stock in a publication titled "Immunomedics Stock H...
IMMU Stock: Bullish on Multiple Time Frames The focus of this publication is Immunomedics, Inc. (NASDAQ: IMMU) stock. This clinical stage biotechnology company develops treatments to boost the body.....
NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Immunomedics, Inc. (NASDAQ: IMMU) will be discussing their earnings results in their Q1 Earnings Call to be held on November 9, 2017 at 5:00 PM Easter...
Immunomedics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Immunomedics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments repo...
Immunotherapy has brought high hopes for cancer treatment, and attracted tremendous resources from the biopharmaceutical community. Here we analyze cancer immunotherapy-related patents granted by the ...
Immunomedics (the âCompanyâ) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune...
Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseas...
We have published hundreds of Immunomedics news stories on BioPortfolio along with dozens of Immunomedics Clinical Trials and PubMed Articles about Immunomedics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunomedics Companies in our database. You can also find out about relevant Immunomedics Drugs and Medications on this site too.
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers) - Mouth cancer can develop on the lip, the tongue, the floor...
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...